Infinimmune Partners with Merck in $838 Million Antibody Discovery Deal
Key Insights
Infinimmune (search) has entered into a collaboration with Merck (search) worth up to $838 million in milestone payments to discover and develop multiple antibodies for undisclosed disease targets.
The partnership leverages Infinimmune (search)'s proprietary Anthrobody® platform that screens millions of human memory B cells combined with AI-guided antibody engineering to identify therapeutic candidates.
Merck (search) will have exclusive rights to develop and commercialize antibody candidates arising from the collaboration, while Infinimmune (search) receives an undisclosed upfront payment.
Biotech company Infinimmune (search) announced a major collaboration with Merck (search) on March 31, 2026, that could generate up to approximately $838 million in milestone payments for the discovery and development of multiple antibodies targeting undisclosed therapeutic areas. The partnership represents a significant validation of Infinimmune's human-first antibody discovery approach and positions the company to scale its proprietary platform.
Platform Technology and Approach
Under the agreement, Infinimmune (search) will deploy its proprietary Anthrobody® discovery platform and GLIMPSE™ antibody language model to identify and optimize therapeutic antibodies derived directly from human immune repertoires. The platform enables screening of millions of single memory B cells across hundreds of potential targets, identifying natively paired antibody candidates with strong affinity, specificity, and favorable drug-like properties.
"By discovering antibodies directly from human immune systems and combining that biology with advanced AI-driven engineering, we can uncover therapeutic opportunities that traditional discovery approaches may not access," said Wyatt McDonnell, Ph.D., CEO and co-founder of Infinimmune (search).
The company's integrated approach combines large-scale single-cell human immune repertoire screening with machine learning-guided antibody engineering to optimize potency, manufacturability, and developability. Infinimmune (search) has built one of the largest datasets of naturally occurring human antibodies, using these data to identify and engineer therapeutic candidates with superior drug characteristics, including high specificity, extended half-life, and reduced immunogenicity.
Deal Structure and Commercial Rights
Merck (search) will receive exclusive rights to develop and commercialize antibody candidates arising from the collaboration. Infinimmune (search) will receive an undisclosed upfront payment and is eligible for milestone payments associated with the progress of multiple antibody candidates totaling up to approximately $838 million.
"Infinimmune (search)'s platform enables the discovery of antibodies directly from the human immune system, offering a compelling new way to access novel biology and promising therapeutic candidates," said Juan Alvarez, Ph.D., Vice President of Biologics Discovery at Merck (search) Research Laboratories.
Infinimmune's Pipeline Development
Beyond the Merck (search) collaboration, Infinimmune (search) is advancing its own pipeline of first- and best-in-class antibodies discovered directly from humans. The company is developing IFX-101 (search), an IL-22 (search) inhibitor, and IFX-201 (search), an IL-13 (search) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (search). Additional pipeline programs are being developed in inflammatory and immunology diseases, including monotherapies inhibiting APRIL (search), IL-17F (search), and other targets.
The collaboration with Merck (search) allows Infinimmune (search) to scale its human-first discovery engine while accelerating the development of differentiated biologics across multiple therapeutic areas. The partnership underscores the pharmaceutical industry's growing interest in platforms that can access novel biology through direct interrogation of human immune responses.